Home>Topics>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR AZN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1- AstraZeneca cancer drug pipeline gets boost from European green light

      Headlines

      Fri, 24 Oct 2014

      * EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)

    2. AstraZeneca ovarian cancer drug wins European green light

      Headlines

      Fri, 24 Oct 2014

      LONDON, Oct 24 (Reuters) - AstraZeneca 's cancer drug pipeline received a boost on Friday as European regulators recommended approval of an experimental medicine against ovarian cancer.

    3. Pfizer's $11 billion buyback plan deflates AstraZeneca bid hopes

      Headlines

      Fri, 24 Oct 2014

      LONDON/NEW YORK (Reuters) - U.S. drugmaker Pfizer is to continue buying back stock, with the board authorizing a new $11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca .

    4. Members of Big Pharma to square off at breast cancer meeting

      Headlines

      Fri, 17 Oct 2014

      and blood cancers. Merck's product, Keytruda (pembrolizumab) injection, is currently cleared for the treatment of melanoma. Bristol-Myers Squibb (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) are also players in the space. 1 comment!

    5. Ad Comm meeting approaches for Novartis' psoriasis therapy candidate

      Headlines

      Thu, 16 Oct 2014

      phototherapy. Briefing docs Psoriasis-related tickers: ( JNJ -1% )( DERM -5% )( MRK -2.2% )( CELG -0.9% )( IDRA +6.8% )( HSP +1.1% )( OTC:CANF )( AMGN -1.5% )( AZN -1.1% )( PFE -1.3% ) Post your comment!

    6. Ironwood Pharma begins linaclotide label expansion trial

      Headlines

      Thu, 16 Oct 2014

      adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. OIC-related tickers: ( SLXP -0.6% )( PGNX +1.9% )( NKTR -0.5% )( AZN -2% )( CBST +0.1% )( SGYP +0.7% ) Post your comment!

    7. AstraZeneca looks to EU decision for next cancer drug boost

      Headlines

      Tue, 14 Oct 2014

      * EU agency to decide on olaparib in ovarian cancer next week

    8. Jeffries' rationale for AstraZeneca upgrade relies on less-than-desirable behavior by management

      Headlines

      Mon, 13 Oct 2014

      Jefferies takes a bit of a different tack . It upgrades AstraZeneca ( AZN +2% ) to "Buy" based on the expectation that management ..... EPS forecast is 10% above consensus for 2015 - 2017. AZN executives would probably describe the situation differently

    9. Texas takes exception to AstraZeneca's marketing of antipsychotic

      Headlines

      Fri, 10 Oct 2014

      a lawsuit in state court accusing AstraZeneca ( AZN +2.9% ) of illegally marketing ..... that have been filed by two former AZN sales reps. The company allegedly ..... market the drug for unapproved uses. AZN settled a Justice Department suit

    10. AstraZeneca ends Targacept partnership

      Headlines

      Thu, 9 Oct 2014

      AstraZeneca (NYSE: AZN ) terminated its December 27, 2005 Collaborative Research and License ..... remaining rights and licenses to compounds granted by Targacept to AstraZeneca will revert back to Targacept, including compound AZD1446 (TC

    « Prev12345Next »
    Content Partners